Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 EP262 in adults with chronic spontaneous urticaria
NL-OMON59889Phase 2Completed
- Sponsor
- Escient Pharmaceuticals
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in chronic idiopathic urticaria (CIU) comparing EP262 with Placebo (2 arms). Primary endpoint: Change in itch intensity and number of hives. Started May 2024; status: completed.
02
Drugs
EP262
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NL-OMON59889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59889.